#USA #Bridgewater #Insmed #Pulmonary Arterial Hypertension #TPIP

Insmed Reports Promising Results from TPIP Study

Insmed Incorporated, a leading biopharmaceutical company, has announced promising data from the ongoing open-label extension study of Treprostinil Palmitil Inhalation Powder (TPIP) in patients diagnosed with Pulmonary Arterial Hypertension (PAH). The 12-month data reflects sustained improvements on various efficacy measures, including a notable reduction in mortality risk based on the REVEAL Lite 2.0 scoring system.

The study comprises a non-placebo controlled approach designed to evaluate long-term safety, tolerability, and effectiveness of TPIP, administered as a once-daily inhaled treatment. Dr. Gene Sullivan, Insmed’s Chief Product Strategy Officer, expressed optimism regarding the results. He noted, "These data signify a critical step in our quest to optimize the potential of treprostinil and provide substantial benefits to those battling PAH."

Key Findings

The findings reveal that TPIP led to significant performance across six-minute walk distance (6MWD), levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), and WHO functional class ratings. The results at the twelve-month mark indicate the following improvements:

• - The TPIP Continued group saw an average improvement of +55.7 meters in 6MWD.
• - In the Placebo Crossed group, the average improvement was +54.1 meters.
• - Both groups experienced approximately a 60% reduction in NT-proBNP concentrations.
• - A majority of patients, between 78% to 80%, achieved WHO Functional Class I or II, reflecting a significant clinical enhancement.

Dr. Raymond Benza from the study’s steering committee commented on the importance of these findings, stating, "The ongoing TPIP OLE study gives clinicians a genuine cause for hope amidst the challenges presented by PAH. The REVEAL Lite 2.0 scores indicated a meaningful improvement, correlating directly with reduced mortality risk and an enhanced quality of life for patients."

Safety Profile and Tolerability

The safety profile of TPIP has been encouraging; no new safety signals emerged through the 12-month study period. The trial monitored a total of 91 patients, and treatment-emergent adverse events (TEAEs) occurred in about 89%. Serious TEAEs were reported in 18.7%, though none were linked to the TPIP treatment directly. The most frequent TEAEs included headaches, cough, and nasopharyngitis but were considered manageable amongst participants.

Next Steps for Insmed

The ongoing developments reinforce Insmed's commitment to advancing TPIP, as it looks forward to kickoff the Phase 3 PALM-PAH study—a double-blind, placebo-controlled trial. This comprehensive study aims to further assess the efficacy and safety of TPIP over twenty-four weeks. Insights obtained from this twelve-month trial are expected to offer a robust foundation for discussions on the future of TPIP in clinical settings.

Insmed’s engagement during the investor call, scheduled for July 16, 2026, emphasizes its dedication to transparency and collaborative efforts moving ahead. The company aims to share and publish further findings from this study to uplift the medical community’s knowledge and support for PAH treatments.

Conclusion

With a focused push towards improving treatment for patients with PAH, Insmed’s advances with TPIP represent both a positive clinical outlook and a reminder of the significant challenges posed by rare diseases. Their latest findings not only provide grounds for optimism but also open a dialogue about the future therapies that could emerge from further developments in PAH treatment modalities.